Rion Co., Ltd. AI Stock Analysis
Want to see JP:6823 full AI Analyst Report?
Rion Co., Ltd. (6823) AI Stock Analysis
Rion Co., Ltd.
(TSE/TYO:6823)
Strong financial performance with a rock-solid balance sheet and consistent profitability is the primary driver, reinforced by attractive valuation metrics; weak technical indicators reflecting bearish momentum partially offset these positives.
Rion Co., Ltd. (6823) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 35.52B
- Dividend Yield
- 3.29%
- Average Volume (3M)
- 54.70K
- Price to Earnings (P/E)
- 10.3
- Beta (1Y)
- 1.11
- Revenue Growth
- 2.48%
- EPS Growth
- 11.44%
- Country
- Japan
- Employees
- 1,003
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Specialties
Rion Co., Ltd. Business Overview & Revenue Model
Company Description
Rion Co., Ltd. develops, manufactures, sells, and services particle counters, medical equipment, and environmental equipment in Japan. The company’s audiological equipment includes hearing instruments, such as analog and digital BTE, trimmer digital...
How the Company Makes Money
Rion generates revenue primarily from the sale of its products in two core areas: (1) acoustic/vibration measurement instruments and related systems, and (2) hearing and audiology-related equipment. In the measurement domain, the company sells instru...
Rion Co., Ltd. Financial Statement Overview
Summary
Strong balance sheet with zero debt and high equity supports stability; solid income growth, healthy margins, and improving cash flows contribute to robust financial health despite moderating revenue growth.
Income Statement
82Very PositiveBalance Sheet
90Very PositiveCash Flow
78Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.17B | 28.50B | 27.88B | 25.73B | 23.87B | 22.64B |
| Gross Profit | 14.19B | 13.98B | 15.35B | 14.33B | 12.69B | 12.22B |
| EBITDA | 5.92B | 5.78B | 5.14B | 4.42B | 3.13B | 3.89B |
| Net Income | 3.47B | 3.35B | 2.86B | 2.65B | 1.80B | 2.23B |
Balance Sheet | ||||||
| Total Assets | 43.16B | 41.78B | 39.13B | 37.40B | 34.81B | 33.42B |
| Cash, Cash Equivalents and Short-Term Investments | 10.65B | 8.56B | 6.01B | 5.03B | 5.37B | 7.72B |
| Total Debt | 0 | 0 | 11.73M | 21.88M | 28.46M | 40.07M |
| Total Liabilities | 7.12B | 6.98B | 7.70B | 8.19B | 8.20B | 8.14B |
| Stockholders Equity | 36.04B | 34.80B | 31.44B | 29.21B | 26.61B | 25.29B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 3.56B | 2.14B | 725.98M | 473.30M | 2.31B |
| Operating Cash Flow | 0 | 4.17B | 3.44B | 2.86B | 1.78B | 2.84B |
| Investing Cash Flow | 0 | -753.08M | -1.69B | -2.65B | -3.25B | -951.93M |
| Financing Cash Flow | 0 | -954.63M | -748.84M | -565.55M | -577.32M | -541.83M |
Rion Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6823, the sentiment is Negative. The current price of 2890.00 is below the 20-day moving average (MA) of 3081.15, below the 50-day MA of 3226.08, and below the 200-day MA of 3219.14, indicating a bearish trend. The MACD of -114.41 indicates Positive momentum. The RSI at 35.97 is Neutral, neither overbought nor oversold. The STOCH value of 73.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6823.
Rion Co., Ltd. Peers Comparison
Overall Rating
JP:667882Outperform
JP:682373Outperform
JP:684963Neutral
JP:652361Neutral
JP:454950Neutral
JP:760045Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | JPY 18.61B | 12.49 | ― | 5.91% | 17.11% | 23.02% | |
| 73Outperform | JPY 35.66B | 10.26 | ― | 3.29% | 2.48% | 11.44% | |
| 63Neutral | JPY 253.13B | 20.90 | ― | 2.07% | -0.18% | -33.38% | |
| 61Neutral | JPY 160.43B | 11.13 | 8.71% | 3.33% | 2.74% | 145.33% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 50Neutral | JPY 73.85B | 39.86 | ― | 2.59% | 3.92% | -52.01% | |
| 45Neutral | JPY 8.08B | -5.20 | ― | 5.54% | -8.68% | -75.03% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:6823 | Rion Co., Ltd. | 2890.00 | 461.58 | 19.01% | |
| JP:6523 | PHC Holdings Corp. | 1260.00 | 343.86 | 37.53% | |
| JP:4549 | Eiken Chemical Co., Ltd. | 2240.00 | -31.71 | -1.40% | |
| JP:6678 | Techno Medica Co., Ltd. | 2184.00 | 300.98 | 15.98% | |
| JP:6849 | Nihon Kohden Corporation | 1544.00 | 19.45 | 1.28% | |
| JP:7600 | Japan Medical Dynamic Marketing, Inc. | 307.00 | -165.70 | -35.05% |
Rion Co., Ltd. Corporate Events
Rion Co. Posts Higher Interim Profits and Confirms Dividend Growth
Rion Co., Ltd. reported consolidated net sales of ¥14.28 billion for the six months ended Sept. 30, 2026, up 4.9% year on year, with operating profit rising 8.3% to ¥2.15 billion and profit attributable to owners of parent climbing 8.7% to ¥1.58 bill...
Rion Completes Restricted Stock Issuance to Directors
Rion Co., Ltd. has completed payment procedures for the issuance of 7,900 shares of common stock as restricted stock compensation to four internal directors, following an earlier announcement in July 2026. The shares, issued at 3,440 yen per share fo...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
